v3.26.1
License Agreement - Additional Information (Details) - USD ($)
$ in Millions
 1 Months Ended 3 Months Ended 12 Months Ended
Aug. 22, 2023
Mar. 23, 2020
Apr. 30, 2024
Apr. 30, 2019
Mar. 31, 2025
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2019
Aug. 31, 2010
License Agreement [Line Items]                    
Annual minimum royalty obligations                   $ 0.2
Seattle Genetics Agreement                    
License Agreement [Line Items]                    
Annual license maintenance fees $ 0.3                  
Transition Agreement [Member]                    
License Agreement [Line Items]                    
Termination date           The Company terminated the Transition Agreement in the first quarter of 2025.        
Astellas Pharma Inc. | Collaboration and License Agreement                    
License Agreement [Line Items]                    
Sublicense fees         $ 0.2   $ 0.6 $ 0.2    
Upfront payment received   $ 80.0                
Immuno Gen Inc                    
License Agreement [Line Items]                    
Milestone payment     $ 5.0              
Clinical Development Milestone Payment     $ 35.0              
Immuno Gen Inc | Collaborative Arrangement                    
License Agreement [Line Items]                    
Upfront payment received                 $ 7.5  
Immuno Gen Inc | Clinical development milestones | Maximum                    
License Agreement [Line Items]                    
Milestone payment                 35.0  
Immuno Gen Inc | Regulatory approval and commercial milestone | Maximum                    
License Agreement [Line Items]                    
Milestone payment                 $ 320.0  
UCSB                    
License Agreement [Line Items]                    
Annual license maintenance fees       $ 0.8            
License payment term       2031            
Percentage of remaining maintenance fees outstanding       50.00%            
Sublicense fees           $ 1.1 $ 1.6